kidney cancer

Renal Cell Carcinoma Space in Focus: Some Key Developments
Renal Cell Carcinoma Space in Focus: Some Key Developments
Yahoo/Zacks.com
renal cell carcinoma
kidney cancer
Exelixis
Roche
Merck
Aveo Oncology
Flag link:
Keytruda combo cleared as first-line kidney cancer treatment in EU
Keytruda combo cleared as first-line kidney cancer treatment in EU
Pharmaforum
Merck
Keytruda
kidney cancer
Europe
Flag link:
Immunicum's dendritic cell therapy flunks co-primary endpoint in 'positive' PhII
Immunicum's dendritic cell therapy flunks co-primary endpoint in 'positive' PhII
Endpoints
Immunicum
immune priming
metastatic kidney cancer
kidney cancer
clinical trials
Flag link:
Exelixis Hits Blockbuster Status
Exelixis Hits Blockbuster Status
Motley Fool
Exelixis
cabozantinib
Cabometx
kidney cancer
liver cancer
Cometriq
thyroid cancer
Flag link:
Merck puts $1B more into oncology, with kidney cancer a focus
Merck puts $1B more into oncology, with kidney cancer a focus
Biopharma Dive
Merck
kidney cancer
M&A
Peloton Therapeutics
Flag link:
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Xconomy
Merck
FDA
Keytruda
kidney cancer
advanced renal cell carcinoma
Inlyta
Flag link:
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Motley Fool
Pfizer
Inlyta
kidney cancer
Merck
Keytruda
Flag link:
Merck, Pfizer drug combo extends kidney cancer survival -study
Merck, Pfizer drug combo extends kidney cancer survival -study
Yahoo/Reuters
Merck
Pfizer
kidney cancer
Keytruda
Inlyta
Sutent
Flag link:
Exelixis Proves Being Second Can Work Out Well
Exelixis Proves Being Second Can Work Out Well
Motley Fool
Exelixis
Bristol-Myers Squibb
Cabometyx
kidney cancer
Flag link:
Aveo stock plunges after delay in FDA approval submission for cancer drug
Aveo stock plunges after delay in FDA approval submission for cancer drug
Bizjournals
Aveo Oncology
kidney cancer
FDA
tivozanib
advanced renal cell carcinoma
Flag link:
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals
Fierce Pharma
Roche
Merck
Pfizer
Tecentriq
kidney cancer
Flag link:
Exelixis Grabs Its Share of the Kidney-Cancer Treatment Market
Exelixis Grabs Its Share of the Kidney-Cancer Treatment Market
Motley Fool
Exelixis
earnings
kidney cancer
Cabometyx
Flag link:
Pfizer preps for BMS showdown with Bavencio kidney cancer combo data
Pfizer preps for BMS showdown with Bavencio kidney cancer combo data
Fierce Pharma
Pfizer
Bristol-Myers Squibb
kidney cancer
Bavencio
Flag link:
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Fierce Pharma
Merck
Keytruda
kidney cancer
Pfizer
Inlyta
Sutent
Flag link:
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
Yahoo/Reuters
Merck KGaA
Bavencio
Pfizer
kidney cancer
Inlyta
Flag link:
Exelixis Gets the Patients Eventually
Exelixis Gets the Patients Eventually
Motley Fool
Exelixis
kidney cancer
renal cell carcinoma
Cabometyx
Flag link:
Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action
Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action
Fierce Pharma
Merck
Eisai
Lenvima
kidney cancer
thyroid cancer
Flag link:
Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer
Bristol's Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
kidney cancer
Flag link:
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Fierce Pharma
Pfizer
renal cell carcinoma
kidney cancer
Inlyta
Flag link:
Novartis offloads failed cancer drug to Oncology Venture
Novartis offloads failed cancer drug to Oncology Venture
Fierce Biotech
Novartis
Oncology Venture
dovitinib
kidney cancer
cancer
Flag link:

Pages